Levormeloxifene

Levormeloxifene
Names
IUPAC name
1-(2-{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine
Identifiers
31477-60-8 N
3D model (Jmol) Interactive image
ChEMBL ChEMBL301327 YesY
ChemSpider 32935 YesY
PubChem 35805
UNII 9512UKZ352 YesY
Properties
C30H35NO3
Molar mass 457.604
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials.[1] It is the enantiomer of ormeloxifene.

References

  1. Ravn P; Nielsen TF; Christiansen C. (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. doi:10.1080/00016340500345691. PMID 16532904.


This article is issued from Wikipedia - version of the 11/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.